Yoshio Sumida, Masashi Yoneda, Hidenori Toyoda, Satoshi Yasuda, Toshifumi Tada, Hideki Hayashi, Yoichi Nishigaki, Yusuke Suzuki, Takafumi Naiki, Asahiro Morishita, Hiroshi Tobita, Shuichi Sato, Naoto Kawabe, Shinya Fukunishi, Tadashi Ikegami, Takaomi Kessoku, Yuji Ogawa, Yasushi Honda, Takashi Nakahara, Kensuke Munekage, Tsunehiro Ochi, Koji Sawada, Atsushi Takahashi, Taeang Arai, Tomomi Kogiso, Satoshi Kimoto, Kengo Tomita, Kazuo Notsumata, Michihiro Nonaka, Kazuhito Kawata, Taro Takami, Takashi Kumada, Eiichi Tomita, Takeshi Okanoue, Atsushi Nakajima, Japan Study Group Of Nafld Jsg-Nafld
International journal of molecular sciences 21(14) 2020年7月13日 査読有り
Type 2 diabetes (T2D) is associated with diabetic nephropathy as well as nonalcoholic steatohepatitis (NASH), which can be called "diabetic hepatopathy or diabetic liver disease". NASH, a severe form of nonalcoholic fatty disease (NAFLD), can sometimes progress to cirrhosis, hepatocellular carcinoma and hepatic failure. T2D patients are at higher risk for liver-related mortality compared with the nondiabetic population. NAFLD is closely associated with chronic kidney disease (CKD) or diabetic nephropathy according to cross-sectional and longitudinal studies. Simultaneous kidney liver transplantation (SKLT) is dramatically increasing in the United States, because NASH-related cirrhosis often complicates end-stage renal disease. Growing evidence suggests that NAFLD and CKD share common pathogenetic mechanisms and potential therapeutic targets. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and diabetic nephropathy/CKD. There are no approved therapies for NASH, but a variety of drug pipelines are now under development. Several agents of them can also ameliorate diabetic nephropathy/CKD, including peroxisome proliferator-activated receptors agonists, apoptosis signaling kinase 1 inhibitor, nuclear factor-erythroid-2-related factor 2 activator, C-C chemokine receptor types 2/5 antagonist and nonsteroidal mineral corticoid receptor antagonist. This review focuses on common drug pipelines in the treatment of diabetic nephropathy and hepatopathy.